Farxiga (Dapagliflozin) for Women 65 and Older: A Caregiver's Complete Guide

What Dapagliflozin Actually Does in an Older Woman's Body

Dapagliflozin belongs to the SGLT2 inhibitor class. It works by blocking sodium-glucose cotransporter 2 in the kidney's proximal tubule, which forces roughly 60-80 grams of glucose per day into the urine rather than reabsorbing it back into the bloodstream. This creates a mild osmotic diuresis, and that diuresis is both the source of benefit and the source of most caregiver concern in women over 65.

Why Physiology Shifts After Menopause

Post-menopausal women have already lost the cardiovascular protection that endogenous estradiol provided during reproductive years. They also tend to have lower lean body mass, reduced renal reserve, and lower baseline blood pressure than younger women on the same medications. Estrogen loss changes the urogenital microbiome: the lactobacillus-dominant environment that protects against yeast and bacterial overgrowth gives way to a higher-pH, flora-depleted state. That shift makes SGLT2-related genital mycotic infections more common and potentially more symptomatic in older women than the trial averages suggest.

Bone mineral density also falls sharply in the decade after menopause. Some SGLT2 inhibitor data have raised a signal around fracture risk, though this appears more pronounced with canagliflozin than with dapagliflozin in head-to-head mechanistic comparisons. A 2022 analysis in the Journal of Clinical Endocrinology and Metabolism found no statistically significant increase in fracture risk specific to dapagliflozin compared with placebo, but older women with pre-existing osteoporosis deserve heightened vigilance about fall prevention, particularly because volume depletion can cause dizziness.

How Kidney Function Changes the Dose

Dapagliflozin's glucose-lowering effect depends on a functioning kidney to filter glucose. As eGFR declines with age, the drug's glycemic benefit shrinks, though its cardio-renal benefits persist at lower eGFR ranges. The FDA prescribing information for Farxiga states:

• For type 2 diabetes: initiate only if eGFR ≥45; discontinue when eGFR falls persistently below 45.
• For heart failure or CKD: can be initiated down to eGFR 25; no glycemic indication below 45 but renal and cardiac benefits continue.

Caregivers should ask the prescriber for the most recent creatinine and eGFR value before every medication refill. Renal function can change quickly in an older woman who has had a urinary tract infection, a hospitalization, or a period of reduced fluid intake.

The DAPA-HF and DAPA-CKD Trials: What the Evidence Looks Like in Older Participants

The two landmark trials that shaped current prescribing in older adults are DAPA-HF and DAPA-CKD. Understanding what they actually showed helps caregivers and patients put risk and benefit in realistic perspective.

DAPA-HF

DAPA-HF enrolled 4,744 patients with heart failure with reduced ejection fraction across 20 countries. The primary composite endpoint of worsening heart failure or cardiovascular death was reduced by 26% with dapagliflozin 10 mg versus placebo (hazard ratio 0.74, 95% CI 0.65-0.85). Mean participant age was 66 years. Women made up only 23% of the trial population, a limitation the authors acknowledged. The benefit was consistent across age subgroups including participants 65 and older, but sex-stratified data for women specifically were not powered for definitive conclusions. This is the evidence gap caregivers deserve to know about.

DAPA-CKD

DAPA-CKD randomized 4,304 adults with CKD stages 2-4 and albuminuria. Dapagliflozin reduced the composite of sustained 50% or greater decline in eGFR, end-stage kidney disease, or renal or cardiovascular death by 39% (HR 0.61, 95% CI 0.51-0.72). Women represented about 33% of participants. Again, the benefit appeared consistent across age subgroups, and the trial was not powered for a sex-specific analysis in older women.

DECLARE-TIMI 58 and Older Women

DECLARE-TIMI 58 was the largest dapagliflozin cardiovascular outcomes trial with 17,160 participants and a broader population including those with multiple cardiovascular risk factors without established disease. Post-menopausal women were well represented. Dapagliflozin did not significantly reduce major adverse cardiovascular events in the overall population but did reduce hospitalization for heart failure and renal progression. This matters for the older woman whose primary concern is staying out of the hospital rather than preventing a first heart attack.

Caregiver Step-by-Step Administration Guide

Before the First Dose

1. Confirm the prescriber has reviewed the most recent eGFR and potassium levels.
2. Check the full medication list for diuretics (furosemide, hydrochlorothiazide, chlorthalidone), ACE inhibitors, ARBs, and insulin or sulfonylureas. Dapagliflozin combined with a loop diuretic significantly raises the risk of volume depletion. The prescriber may reduce the diuretic dose when starting dapagliflozin.
3. Establish a baseline blood pressure reading at home. Record morning and evening readings for the first two weeks.

Daily Administration

Give the tablet once daily in the morning, at approximately the same time each day. Food does not affect absorption. If the woman has difficulty swallowing tablets, the tablet can be crushed and mixed with a small amount of water; there is no extended-release coating to preserve. The Farxiga prescribing label does not restrict administration with food or list a requirement to swallow whole, so crushing is a reasonable practical option when swallowing is difficult, though caregivers should confirm with the dispensing pharmacist.

Hydration: The Number One Daily Task

The osmotic diuresis from SGLT2 inhibition causes older women to lose more fluid through urine than they expect. A woman who was already drinking less fluid due to incontinence concerns or reduced thirst perception faces double jeopardy. The general guidance is to aim for at least six to eight 8-ounce glasses of water daily unless the prescriber has set a fluid restriction for heart failure. Document fluid intake if the woman is frail or has a history of recurrent UTIs.

Monitoring for Volume Depletion

Teach every caregiver these specific warning signs:

• Dizziness or lightheadedness when standing up from a chair or bed
• Dry mouth or cracked lips that are new or worsening
• Darker urine than usual (concentrated urine)
• Confusion or unusual drowsiness, which in older women may be the only sign of early dehydration
• Blood pressure reading 20 mmHg or more lower than the established baseline when standing

If two or more of these signs appear together, hold the dose and call the prescriber that day.

Infection Risks: UTI and Genital Mycotic Infections in Post-Menopausal Women

This is where older women differ most from younger adults in the dapagliflozin profile. Glucose in the urine is a growth medium for bacteria and yeast. Post-menopausal women already have a urogenital environment that is more hospitable to both.

Genital Yeast Infections

In the DECLARE-TIMI 58 trial, genital mycotic infections occurred in approximately 6.6% of women taking dapagliflozin versus 1.4% in the placebo group. This rate was higher in women than in men throughout the trial. For a post-menopausal woman who may also have genitourinary syndrome of menopause (GSM) causing vulvovaginal atrophy, a yeast infection can be more painful and slower to resolve than it would be in a younger woman with intact estrogenized tissue.

Caregivers should watch for:

• New vaginal discharge that is thick or white
• Persistent itching or burning in the genital area
• Complaints of discomfort that the woman may describe vaguely or attribute to "normal aging"

Topical antifungals (clotrimazole, miconazole) are first-line treatment. Recurrent infections may warrant discussion with the prescriber about low-dose vaginal estrogen to restore the protective vaginal flora, which is safe to use concurrently with dapagliflozin.

Urinary Tract Infections

The overall UTI signal with dapagliflozin is modest compared with other SGLT2 inhibitors, but older women on dapagliflozin who develop a UTI are at higher risk of it ascending to a kidney infection (pyelonephritis) if not caught early. A 2019 FDA Drug Safety Communication reinforced that Fournier's gangrene (necrotizing fasciitis of the perineum), though rare, has been reported with the SGLT2 class and warrants immediate emergency care if any genital area pain, redness, or swelling with fever develops. This is not a reason to avoid the drug, but it is a reason for caregivers to act quickly when genital symptoms appear.

Signs of UTI to report promptly:

• Burning or pain during urination
• Frequency or urgency beyond the woman's normal pattern
• Fever above 38°C (100.4°F)
• New back pain at the flank level
• Cloudy or foul-smelling urine

Diabetic Ketoacidosis: A Risk That Looks Different in Older Women

Euglycemic diabetic ketoacidosis (euDKA) is a rare but life-threatening complication of SGLT2 inhibitors in which ketones accumulate even when blood glucose appears near-normal. The FDA issued a safety communication in 2015 and updated it in subsequent years warning prescribers and patients about this risk.

Older women who are frail, eating very little, or who have had a recent illness, surgery, or prolonged fasting are at highest risk. Because blood glucose may remain below 250 mg/dL in euDKA, it is often missed if caregivers check only glucose.

Hold dapagliflozin and call the prescriber if the woman has had nothing by mouth for more than 24 hours, is preparing for surgery, or has any acute illness with vomiting. The prescriber will typically instruct you to restart it only after she is eating and drinking normally again.

Symptoms to recognize:

• Nausea, vomiting, or abdominal pain
• Rapid or labored breathing
• Confusion or unusual fatigue not explained by poor sleep
• Fruity smell on the breath

Bone Health, Falls, and the Older Woman on Dapagliflozin

The following framework is designed to help caregivers systematically assess fall and fracture risk for older women on SGLT2 inhibitors, because no single published checklist covers both the drug-specific and post-menopausal factors simultaneously.

The WomanRx SGLT2 Fall-Risk Checklist for Women 65 and Older:

| Risk Factor | Why It Matters on Dapagliflozin | Action | |---|---|---| | Orthostatic hypotension at baseline | Volume depletion amplifies the drop | Daily standing BP check for first 4 weeks | | On a loop or thiazide diuretic | Additive fluid loss | Ask prescriber about dose reduction | | Pre-existing osteoporosis (T-score ≤-2.5) | Any fall carries high fracture risk | Confirm bisphosphonate or other bone agent is current | | DEXA not done in past 2 years | Bone status unknown | Request DEXA; ACOG and NOF recommend it for all women 65+ | | Uses a walker or cane | Balance already compromised | Extra caution with morning dose timing | | Has had a fall in past 12 months | Single strongest predictor of future fall | Physical therapy referral; review all fall-risk meds | | Vitamin D level <30 ng/mL | Low D impairs muscle function and balance | Supplement 1,000-2,000 IU daily per discussion with prescriber |

The American College of Obstetricians and Gynecologists recommends bone density screening for all women beginning at age 65 regardless of risk factors, making it an appropriate starting point for any woman new to dapagliflozin who has not had a recent DEXA scan.

Pregnancy, Lactation, and Contraception

Dapagliflozin is contraindicated during the second and third trimesters of pregnancy based on animal data showing fetal renal toxicity and adverse kidney development. The Farxiga prescribing information states the drug should be discontinued as soon as pregnancy is detected.

For women 65 and older, pregnancy is exceptionally rare but not impossible in early perimenopause for women in their early-to-mid sixties who have not reached 12 consecutive months without a period. Any woman in this group who has not confirmed menopause through clinical assessment should use reliable contraception.

Lactation data for dapagliflozin in humans is absent. Animal studies show drug transfer into milk. Because of the potential for serious adverse renal effects in a nursing infant and the absence of human safety data, the prescribing label advises against use during breastfeeding. At age 65 and above, breastfeeding is not a clinical consideration for the vast majority of patients, but it is worth documenting in any woman who is caring for a grandchild and whose prescriber may not have asked.

Who This Drug Is Right For (and Who Should Pause)

Strong Candidates Among Women 65 and Older

• Post-menopausal woman with type 2 diabetes and eGFR ≥45, particularly if she has albuminuria (urinary albumin-to-creatinine ratio above 200 mg/g), where kidney protection is a primary goal
• Woman with heart failure with reduced ejection fraction (HFrEF) already on guideline-directed therapy including beta-blockers and ACE inhibitors or ARBs, where dapagliflozin adds a 26% reduction in the composite endpoint regardless of diabetes status per DAPA-HF
• Woman with CKD stages 2-4 with proteinuria where the DAPA-CKD trial showed a 39% reduction in kidney disease progression per McMurray et al., NEJM 2019 (DAPA-HF) and Heerspink et al., NEJM 2020 (DAPA-CKD)
• Woman with heart failure with preserved ejection fraction (HFpEF), which is more common in older women than older men; the DELIVER trial showed dapagliflozin reduced worsening heart failure or cardiovascular death by 18% (HR 0.82, 95% CI 0.73-0.92) in this population

Women Who Need Extra Caution or Should Not Start

• eGFR persistently below 25: drug is unlikely to be effective and fluid losses may cause harm
• Recurrent severe UTIs or a history of urosepsis: the glucosuria effect may perpetuate infections
• Active genitourinary cancer or recent pelvic radiation: urogenital tissue is already compromised
• Severe frailty with very low caloric intake: euDKA risk outweighs likely benefit
• Currently using insulin or a sulfonylurea without close glucose monitoring in place: hypoglycemia risk from the combination, though dapagliflozin alone does not cause hypoglycemia

Practical Caregiver Checklist: Daily, Weekly, and Monthly

Every Day

• Give tablet at the same morning time
• Encourage six to eight glasses of water
• Note any complaints of dizziness, genital itching, or urinary symptoms

Every Week

• Review the blood pressure log and compare standing versus seated readings
• Ask the woman directly about genital or urinary symptoms (she may not volunteer them)
• Check that she has enough tablets; dapagliflozin should not be interrupted abruptly if possible

Every Month

• Review blood glucose log (if she has diabetes) with the prescriber at scheduled visits
• Confirm no new medications have been added that interact (NSAIDs increase volume depletion risk; rifampin reduces dapagliflozin exposure by about 22% per the FDA label)
• Ask whether a repeat metabolic panel (creatinine, eGFR, potassium) is due

When to Call the Prescriber Versus When to Go to the Emergency Room

Call the Prescriber Same Day

• First-time yeast infection or UTI symptoms
• Blood pressure consistently 20 mmHg lower when standing than sitting
• She has not eaten or drunk fluids in over 12 hours due to illness
• New foot swelling (may indicate she needs a diuretic dose re-check)

Go to the Emergency Room

• Symptoms of euDKA: nausea, vomiting, rapid breathing, confusion, even if glucose meter reads under 250 mg/dL
• Signs of Fournier's gangrene: genital or perineal pain, redness, swelling, with any fever
• Fall with possible fracture
• Altered consciousness or inability to stay awake

A Note on the Evidence Gap for Older Women

WomanRx editorial board member Dr. Maya Okafor, MD, summarizes the clinical reality directly: "The major SGLT2 trials enrolled about 23 to 33 percent women, and none were powered to report sex-stratified outcomes in women over 65 specifically. What we have is subgroup consistency suggesting the benefits hold, but caregivers and patients deserve to know that when we quote a 26% reduction in heart failure events, that number comes primarily from a trial where three out of four participants were men. We extrapolate, and we do so with reasonable confidence, but we do not have the definitive female-specific data we should."

This matters because women 65 and older with heart failure are more likely to have HFpEF than HFrEF, are more likely to be on multiple medications for comorbidities including osteoporosis and GSM, and are more likely to experience symptomatic orthostatic hypotension. These factors require individualized assessment rather than direct application of trial averages.